Antengene raises $120m amid China anti-cancer push

It is the fourth nine-figure private fundraising by a Chinese pharmaceutical company involved in cancer research in nine months.

Antengene raises $120m amid China anti-cancer push

Antengene has become the fourth Chinese biopharmaceutical company in less than a year to raise well over $100 million from private investors, illustrating the country's growing efforts to develop effective anti-cancer drugs.

Shanghai-based Antengene said it completed a $120 million Series B fundraising on Wednesday to finance more research and invest in marketing for its ATG-008 anti-cancer drug, which is already undergoing Phase II clinical trials and so is being tried...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Print Edition

FinanceAsia Print Edition